Rocaglamide Liposomes, Formulation KHE9A
$1,295.00 – $3,295.00
PEGylated liposomes containing Rocaglamide (Roc-A). Rocaglamide is a potent inhibitor of NF-κB activation in T-cells. Rocaglamide is a potent and selective HSF1 activation inhibitor (IC50 ~50 nM). Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also exhibits anti-leukemia activity. Rocaglamide is insoluble in aqueous media. This product is a pre-formulated liposomal version of Rocaglamide which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
We synthesize custom liposomes like this. To see a full list of our formulation capabilities, click here.
Figure 1 (Thumbnail). Solubilization of Rocaglamide (Roc-A) by liposomes. Rocaglamide is shown under magnification in free or liposomal forms at 4.0 mg/mL. Left: Rocaglamide is insoluble in aqueous media. Rocaglamide was dissolved in DMSO and diluted in 322 Buffer (292 mM sucrose, 0.5% DPBS) to examine aqueous solubility. Right: Matched concentration of Rocaglamide is shown in liposomal form (formulation KHE9A) in the same bulk solution.
PEGylated liposomes loaded with Rocaglamide (Roc-A)
|Concentration Total Lipid||60 mM|
|Concentration Rocaglamide||4.0 mg/mL (± ~5%)|
|Hydration Solution||292 mM sucrose, 0.5% DPBS (1X)|
|External Solution||292 mM sucrose, 0.5% DPBS (1X)|
|Liposome Avg. Size||70-120 nm|
Bioactive Compound Details
|Target(s)||NFκB, HSF1, eIF4A|
|Signaling Pathway||NFκB pathway, heat shock response|
|2 °C to 8 °C (do not freeze), protect from light|
|Shelf Life*||At least 1 month|
*Product is too new for long-term stability data. This section will be updated regularly as new data becomes available.